Sunday, October 23, 2005

4:00–6:00pm
Registration & Welcome Reception

Monday October 24, 2005

7:00 am–7:00pm
Conference Registration and Information Desk Open

7:00-8:30am
Breakfast Reception

8:30–8:45am
Welcome and Introduction

Peter Hebert, CEO, Lux Research Inc.

8:45–9:15am
Nanotechnology, Innovation, and Economic Impact
Speaker TBA

9:15–10:00am
Myth vs. Reality: Where Nanotech Creates Value for Corporations and Investors

Matthew M. Nordan, Vice President of Research, Lux Research Inc.

Nanotechnology has been hailed as the next industrial revolution, offering opportunities to create value that leading corporations and investors can exploit. Who will win and lose as nanotechnology pervades products ranging from cars to cancer therapy to consumer goods? This session will synthesize Lux Research’s exclusive, proprietary analysis to chart a roadmap for nanotechnology commercialization across industries and product categories.

It will cover:
The state of global nanotechnology commercialization today
The outlook for this decade on the scientific, commercial, and investment fronts
How corporations, start-ups, investors, and governments will capture value from nanotech development
How to avoid making costly mistakes based on myths and pipe dreams

10:00–10:45am
Exploiting Nanotech for Competitive Advantage
Speaker TBA

This session will cover:
Quick wins in near-term nanotechnology
Implementing an efficient nanotechnology R&D program that will deliver benefits directly to business units
Using nanotechnology for bottom-line cost cutting
Building IP barriers in nanotechnology

10:45-11:15am
Networking Break

11:15-12:00pm
Nanotech, Health, and Society

Hamilton Jordan, Former Chief of Staff, White House

Many see nanotechnology as a potential force for public good. Medical applications in particular have captured the public’s attention because the direct benefits are tangible and extremely desirable. This session will assess nanotechnology’s impact on health care and society from the perspective of Hamilton Jordan, who brings unique insight both from his experience directing policy decisions in the White House and from his personal victories as a four-time cancer survivor.

This session will cover:
Nanotech solutions being developed for pervasive problems in developing countries
The integration of technology, policy and society in the real world
How companies and investors can “do well” while “doing good”
The personal story of Hamilton’s victory over cancer
2 Proprietary and confidential information of Lux Research Inc. All rights reserved 8/11/05

12:00 –12:45pm
Nanotech on the Front Lines: Military and Defense Applications

William Schneider, Chairman, Defense Science Board
Timothy Swager, Associate Director, MIT Institute for Soldier Nanotechnologies
Lisa Rutherford, Principal, In-Q-Tel (venture capital organization funded by the Central Intelligence Agency)

Military and defense applications of nanotechnology are on the front lines of innovation and government investment. Federal funding for advanced technology in general has historically been driven by wartime needs, with industry cherry pickers following closely to harvest the most promising results for commercial applications; Nanotechnology is proving to be no different. This session will explore how various agencies representing the intelligence community and the armed forces are monitoring, making investments in, and using nanotechnology.

It will cover:
Military and defense funding for nanotechnology at home and abroad
The development of countermeasures to protect against nanotechnology threats
Warfighter protection systems
How commercial entities can benefit from military and defense applications in nanotech

12:45-1:30pm
Lunch

1:30-2:00pm
Networking Coffee and Dessert

2:00-2:45pm
What It’s Worth: Determining Valuation for Nanotech Specialists

David Lackner, Senior Analyst, Lux Research

Nanotechnology specialists – start-up and small-cap companies – are already working with
corporate buyers to deliver innovative materials and components. The challenge: Specialists and buyers have very different expectations as to how much value these innovations add and how they should be priced. The outcome of this disconnect will determine the stock market valuations that nanotech specialists can justify and the premiums that corporate buyers will have to pay for their products.

This session will cover:
The “tug of war” between nanotech specialists and corporate buyers
Approaches and strategies to pricing nanotechnology enabled goods, based on case studies of real products sold today
The outlook for nano-enabled products to command premium prices Comparables that corporations and investors can use to make wise valuation decisions

2:45-3:30pm
Manufacturing Nanotechnology Profits: How Blue-Chip Industrials are Exploiting Nanotech

David Diehl, Senior Scientist, PPG Industries
Additional Speakers TBA

Much attention in nanotechnology focuses on start-up companies, whiz-bang electronic applications, and life sciences innovations. But nanotechnology's impact is being felt first among blue-chip industrial companies that have the manufacturing and distribution capability to bring nanotech innovations to market. These firms have quietly turned nanoenabled composite materials, coatings, and industrial products into product lines accountable for billions of dollars in revenue. This session will assemble some of nanotechnology's most aggressive industrialists to describe how nanotech is driving revenue and profit for them today, covering:

Establishment of a nanotechnology strategy in a complex, multinational organization
Best practices in working with suppliers/customers to get nanotech innovations to market
The outlook for nanotech's contribution to the top and bottom lines in large industrial companies The benefits and risks of using "nano" nomenclature in marketing and advertising products
Presentations from Presenting Sponsors
3 Proprietary and confidential information of Lux Research Inc. All rights reserved 8/11/05

3:30-4:00pm
Networking Break

4:00-4:45pm
Strategies from Asia’s Nanotech Innovators

Moderator: David Lackner, Senior Analyst, Lux Research
Dr. Jong-Min Kim, Materials Lab Director, Samsung Advanced Institute of Technology
Additional Speakers TBA

Asia’s innovation prowess is well known. The region is investing heavily in nanotechnology and stands ready to exploit its comparative advantages in high-tech manufacturing to profit from nanotech commercialization. From metal oxide nanoparticles to next-generation batteries and large-screen displays, Korean, Japanese, and Chinese companies are pursuing a multitude of research programs and delivering products incorporating nanotechnology today. This session will uncover how Asian innovators exploit nanotechnology for competitive advantage, covering:

Current activities at panelists’ companies in nanotechnology
Specific nano-enabled applications and products that Asia is leading the world in
How Asian companies collaborate with one another – as well as public sector programs – to bring nanotechnology innovations to market fast
How Western start-ups, corporations, and investors can build profitable Asian relationships in nanotech
Presentations from our Presenting Sponsors

4:45-5:30pm
Mastering the Disruptive Wave: Lessons for Nanotechnology Investors and Innovators

James Surowiecki, Columnist, The New Yorker; Author, “The Wisdom of Crowds”

Nanotechnology has been hailed, hyped, and now accepted as a disruptive family of technologies. While every innovative idea – whether a social change or technological shift – appears to be completely unique, historical analogies in fact provide valuable guideposts for determining their impact on business and society. In this session, celebrated author James Surowiecki will discuss how nanotech compares with revolutions across fields as diverse as popular culture, psychology, ant biology, economic behaviorism, artificial intelligence, military history and political theory.

This session will cover:
Emerging technology waves of the past and what they teach us about nanotechnology
How nanotechnology lends itself to development by “smart crowds”
Scenarios for the future adoption of nanotechnology
How innovations across multiple industries alter business and consumer behavior patterns

5:30-5:45pm
Wrap Up
Matthew M. Nordan, Vice President of Research, Lux Research, Inc.

5:45–7:45pm
Evening Reception

Tuesday, October 25, 2005

7:00–8:00am
Breakfast Reception

8:00–8:15am
Day Two Welcome

Matthew M. Nordan, Vice President of Research, Lux Research, Inc.

8:15–9:00am
Investing in Nanotechnology – Wisely

Peter Hebert, Chairman & CEO, Lux Research Inc.

Nanotechnology commercialization is becoming widespread. A third of companies in the Dow Jones Industrial Average are conducting nanotechnology research, and nanotech start-up IPOs are in the pipeline for 2006. Despite this activity, good investments are hard to come by. As more publicly traded companies exploiting nanotech emerge, investors must understand how to make sense of the opportunities – both for start-ups and corporations, and for long and short positions. This session will provide a critical handbook for nanotech investing in public markets, referring to the Lux Research Index (AMEX:LUXNI) as a benchmark.

It will cover:
The universe of investment opportunities in nanotechnology today
The metrics that matter most in performing due diligence on nanotech investments
How techniques like paired trades can be used to establish valuable positions today
How the universe of nanotech investments will change over time

9:00–9:45am
The Semiconductor Industry’s Nanotech Future
Paolo Gargini, Director of Technology, Intel
The semiconductor industry has worked at the nanoscale for years. Now, emerging nanotechnology innovations ranging from nanoimprint lithography to carbon nanotubes and silicon nanowires promise new options to keep Moore’s Law humming in the coming decades. This session will show how the semiconductor industry can exploit nanoscale innovations, from today’s strained silicon to tomorrow’s bio-directed self-assembly, to maintain its pace. Paolo Gargini will bring unique perspective both as Director of Technology at Intel and as the head of the industry “bible,” the International Roadmap for Semiconductors. This session will cover:
Intel’s nanotechnology roadmap and that of the Semiconductor Industry Association (SIA)
Expectations for a nanotech future: The next ten years of CMOS and the integration of nanotechnology
The brick wall ahead: Economic and technical challenges
How nanotechnology will deliver both performance improvements and new applications in semiconductors

9:45–10:00am
Networking Break

10:00-10:45am
Best Practices of Nanotech Serial Entrepreneurs
Moderator: Jason Pontin, Editor and Chief, Technology Review
Larry Bock, Founder and CEO, Nanosys
Howard Berke, Chairman/CEO, Konarka Technologies, Inc.
David Soane, Founder of Nano-Tex, Aclara Biosciences, Innovative Construction and Building Materials; CEO,
Soane Labs
The CEOs and technical founders who build valuable companies again and again seem to have entrepreneurship in their blood, and they are attacking nanotechnology with vigor. These business-builders have a recipe for success and an uncanny knack for knowing how to match technologies to relevant applications. They also have the determination to persist no matter what hurdles confront them. At this session three serial entrepreneurs – leading lights of nanotech commercialization – will discuss their formulas for success, covering: What makes building a nanotech start-up unique How to raise funds, engage partners, and make a successful exit based on a “nanotech story” Lessons learned in building nanotech ventures The outlook of nanotech start-ups and their ability to access public markets

10:45-11:00am
Networking Break
5 Proprietary and confidential information of Lux Research Inc. All rights reserved 8/11/05

11:00-11:45am
Finance and Investment Breakout Low Odds, High Stakes: Private Investments in Nanotechnology
Bryan Roberts, General Partner, Venrock Assoc.
Additional Panelists to be announced

Private investments in nanotechnology tempt investors with substantial payoffs, but the technologies are often raw and the stakes are high. At this session, eminent venture capital investors in nanotechnology will describe how they pick winners among the more than 1,200 nanotech start-ups operating worldwide.

This session will cover:
The state of nanotechnology venture investing today
The ripeness factor: When to make an investment in nanotechnology
When nanotech start-ups should pursue venture versus grant, debt, joint development, and other forms of financing
How venture investors value nanotech startups – and what exits they expect
Innovation and Science Breakout

Nanotech Innovation Outlook: Leading Scientists< Identify Game-Changing Technologies

Moderator: Elizabeth Corcoran, Senior Editor, Forbes
Paul Alivasatos, Professor of Chemistry and Materials Science, UC Berkeley
Chad Mirkin, Director, Institute for Nanotechnology
Phil Kuekes, Computer Architect, HP Labs
Bob Iannucci, SVP Head of Research Center, Nokia

Corporate executives and institutional investors looking for the “next big thing” in nanotechnology can be easily distracted by hype. How to separate the wheat from the chaff? In this session, leading scientists on the cutting edge of nanotechnology commercialization at leading corporations, start-ups, and academic institutions will distinguish hype from reality – and give their take on which technologies are ready for prime time.

The session will cover:
The true state of affairs in long-term nanotechnology R&D
When killer nanotechnology applications will be ready for the market
Success strategies for collaboration between scientists and business-focused executives
Game-changers: Catalysts for accelerating research out of the lab

11:45–12:00pm
Networking Break

12:00–12:45pm
Word on The Street: Public Investors’ Views
on Nanotech

Moderator: Josh Wolfe, Co-founder and Managing Partner, Lux Capital; Editor, Forbes/Wolfe Nanotech Report
Michael Mauboussin, Chief Investment Strategist, Legg Mason Pip Coburn, Chief Technology Strategist, UBS Warburg

Fund managers don’t have much to invest in yet when it comes to nanotechnology, but they are increasingly monitoring the field and initiating coverage on pioneers. In this session, premier technology investment strategists will describe how they view nanotech and identify the metrics that they care about when it comes to valuation.

It will cover:
Public-market investment strategies for nanotechnology
How nanotechnology will impact existing investment portfolios
What investment strategies look for in a small- and mid-cap companies focused on nanotech
How premier investors view horizontal technologies that cut across multiple industries

Case Studies: Promising Nanotechnology Startups, from Stealth Mode to Profitability

Moderator: William Sahlman, Professor, Harvard Business School
Norm Schumaker, Co-Founder and CEO, Molecular Imprints
Donn Tice, CEO, Nano-Tex
Mike Knapp, CEO, Cambrios Technologies
Nanotech start-ups begin life in stealth mode, keeping a low profile in order to maximize competitive advantage. Three years on from the nanotech venture capital boom in 2002, many start-ups are now maturing and preparing to do initial public offerings or seek trade sales. In this session, chief executives from companies across this commercialization spectrum will discuss their experiences and offer best practices in going from the lab to Wall Street.

It will cover:
When to run silently versus when to publicize a start-up’s story
Tools to gain competitive advantage and keep it
Considerations in engaging with partners and customers across the start-up life cycle
Developing – and selling – a vision to investors from venture capital to public markets

12:45–2:00pm
Lunch and Networking Dessert Reception

2:00–2:45pm
How Leading Countries Compare in Nanotech: A Lux Research Competitive Benchmark
F. Mark Modzelewski, Cofounder, Lux Research and Cofounder NanoBusiness Alliance

Nanotechnology is attracting increased government investment and industry attention worldwide, from nanotech stalwarts like Japan and the U.S. to up-and-comers like Australia and Israel. This session will rank nations on their potential to create jobs and attract inward investment from their nanotechnology efforts; based on their level of nanotechnology activity and demonstrated prowess at commercializing advanced technology in general.

It willcover:
How specific countries in the Asia/Pacific, North American, and European regions compare on nanotechnology
How the density of start-ups, major corporations, and government initiatives active in nanotechnology differ by country
Which countries lead in which specific application domains Site selection decisions for corporations

2:45–3:30pm
Nanotechnology’s Impact on Healthcare and Life Sciences
Norbert Riedel, Chief Scientific Officer, Baxter International

Healthcare and life sciences stand to gain a great deal by incorporating nanotechnology for everything from drug discovery to tissue regeneration. In this session, Baxter Chief Science Officer Norbert Riedel will deliver his prognosis on nanotechnology in life sciences, drawing on his experience in the growth of the biotech industry, and highlighting Baxter’s NanoEdge drug delivery platform as well as its internal R&D in other areas.

This session will cover:
The state of healthcare and life sciences research today
How nanotechnology will impact healthcare and life sciences over the next five years
What’s the same and what’s different in comparing nanotechnology to biotechnology
Killer applications for nanotechnology in healthcare and life sciences

3:30-4:15pm
The Environmental, Health, and Safety Risks of Nanotech: Panel Debate
Moderator: Sean Murdock, Executive Director, NanoBusiness Alliance
Vicki Colvin, Professor, Rice University; Director, Center for Biological and Environmental Nanotechnology; cofounder, International Council on Nanotechnology
Pat Roy Mooney, Executive Director, ETC Group

Nanotechnology’s environmental, health, and safety risks fall into two classes: Real risks that nanoparticles may be hazardous, and perceptual risk that they might be even if they’re not. Real risks brought down asbestos, while genetically modified organisms suffered from perceptual ones. This panel session will discuss the roles that corporations, start-ups, public policy makers, and even investors have to play in ensuring the nanotechnology applications are developed responsibly – and that perceptual risks don’t become disconnected from real ones. This session will cover: The state of research on nanotechnology environmental, health, and safety risks The implications for the public, the environment, corporations, investors, start-ups, and policymakers in nanotech Responsible corporate behavior when it comes to handling and commercializing nanomaterials Educational programs to help align consumer perceptions with scientific reality.

4:15–4:30pm
Wrap Up
Matthew Nordan, Vice President Research, Lux Research Inc.

Cambridge, MA

October 24-25, 2005
$1695

Event Overview

Agenda

Speakers

Sponsors

Conference Packs